The following is a summary of “An Updated Review of Immune Checkpoint Inhibitors in Cutaneous Oncology: Beyond Melanoma,” ...

Shares of Replimune Group, Inc. (NASDAQ: NASDAQ:REPL) surged 17% following the announcement that the U.S. Food and Drug ...

The confirmatory IGNYTE-3 trial is assessing RP1 in combination with nivolumab in patients with advanced melanoma who have progressed on anti-PD-1 and anti-CTLA-4 therapies or are ineligible for ...

The study is based on the analysis of human senescent cells in a specific tumor model — melanoma, which affects skin cells known as melanocytes — and, more specifically, melanocytes exposed to ...

(RTTNews) - Replimune Group, Inc. (REPL), Tuesday announced that the U.S. Food and Drug Administration has accepted the Biologics License Application for RP1 in combination with Nivolumab for the ...

A history of childhood cancer more than doubled the risk of melanoma and premature death in adults, a large retrospective ...

The biologics license application for RP1 (vusolimogene oderparepvec) plus nivolumab in advanced melanoma was accepted by the ...

Evaxion Biotech has completed subject dosing in the Phase II trial of EVX-01, for the treatment of advanced melanoma.

A topical treatment combining calcipotriol and 5-FU shows promise in reducing premalignant lesions and lowering skin cancer ...

Moles appear commonly on human skin, yet their presence demands attention and regular monitoring. While most remain harmless, ...

Cancers of the eye are exceedingly rare, and only a rare handful of cancer clinics in the nation are equipped to deal with ...